Based on the CHASE trial results, KALA plans to cease development of KPI-012 and its mesenchymal stem cell secretome platform. KALA plans to evaluate its strategic options and as part of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback